A30.4

Clinical Causes: Prolonged exposure to Mycobacterium leprae bacteria, typically through respiratory droplets from an infected person. Transmission generally occurs via respiratory routes, although direct contact with skin lesions may also contribute. Genetic susceptibility may influence an individual's risk of developing the disease. Environmental factors, such as living conditions and socioeconomic status, can affect exposure risks.

Key Symptoms: Multiple skin lesions which may be less numb and more erythematous or hypopigmented. Nerve involvement leading to numbness or tingling, particularly in the skin of extremities. Loss of sensation in affected skin areas, increasing for potential injuries or infections. Mild to moderate muscle weakness or atrophy in affected regions. Presence of nodules or plaques on the skin, often with symmetrical distribution. Low-grade fever or malaise in some cases, indicating ongoing immune response.

Diagnosis Path: Diagnosis involves a combination of clinical assessment and laboratory tests. Healthcare providers typically look for characteristic skin lesions, nerve impairment, and sensory loss. Laboratory confirmation can include skin smears or biopsies showing acid-fast bacilli. Additional tests like slit-skin smears assist in quantifying bacterial load. Molecular techniques such as PCR may be used for more sensitive detection. The classification into borderline lepromatous leprosy is based on the number and type of skin lesions, nerve involvement, and bacterial presence.

Treatment Protocols: Treatment primarily consists of multidrug therapy (MDT), recommended by the World Health Organization. The regimen usually involves a combination of antibiotics such as dapsone, rifampicin, and clofazimine, administered over several months to years depending on disease severity and response. Regular medical follow-up ensures effective management and monitoring for potential reactions or complications. Patient support and education are key components to improve adherence and reduce stigma associated with the disease.